Recurrent Acute Lymphoblastic Leukemia

Oncology·MeSH: Precursor Cell Lymphoblastic Leukemia-Lymphoma

Prevalence

8.0 / 100K

Incidence

1.8 / 100K/yr

11 drugs in development·4 companies·6 clinical trials

Drug Pipeline by Phase

Phase 3(2)

Drug	Company
Clofarabine	Merus N.V. (MRUS)
Ofatumumab	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 2(8)

Drug	Company
Bortezomib	Structure Therapeutics Inc. (GPCR)
Clofarabine	ENANTA PHARMACEUTICALS INC (ENTA)
Clofarabine	Structure Therapeutics Inc. (GPCR)
Etoposide	Structure Therapeutics Inc. (GPCR)
Ofatumumab	Merus N.V. (MRUS)
Ofatumumab	Structure Therapeutics Inc. (GPCR)
Ofatumumab	Filana Therapeutics Inc. (FLNA)
Vincristine Sulfate Liposome	Structure Therapeutics Inc. (GPCR)

Phase 4(1)

Drug	Company
Clofarabine	Filana Therapeutics Inc. (FLNA)

BioSniper tracks 11 drugs in development for Recurrent Acute Lymphoblastic Leukemia across 4 companies.

There are 6 clinical trials targeting Recurrent Acute Lymphoblastic Leukemia tracked by BioSniper.

The estimated prevalence of Recurrent Acute Lymphoblastic Leukemia is approximately 8.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.